Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CK Regeon Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: Korea
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Diabetic Foot|Skin Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
COSMOS-21-RegenT-1 | P1 |
Completed |
Skin Ulcer|Diabetic Foot |
2024-01-08 |